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(57) ABSTRACT 
A method of sensing glucose in subjects includes the steps of 
providing a sensing solution including a plurality of metal 
ions, introducing a bodily fluid sample from a subject into the 
sensing solution. An optically-based measurable derived 
from directing incident light on the solution is generated. The 
concentration of glucose in the bodily fluid using the measur-
able is then determined which permits the blood glucose level 
to be derived. 
23 Claims, 3 Drawing Sheets 
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NONINVASIVE GLUCOSE MONITOR 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
The present application claims priority to U.S. Provisional 
Patent Application Ser. No. 60/839,757 filed Aug. 24, 2006, 
entitled "NONINVASIVE GLUCOSE MONITOR". 
2 
converted into a glucose concentration. After 72 hours of 
measurements, the device is removed and plugged into a 
docking station to download its readings. 
The docking station can be connected to a computer that 
contains dedicated software for use with the system. The 
computer will then print out a graph of the three days' blood 
glucose readings. The CGMS must be recalibrated with a 
fingerstick blood glucose reading at least four times per day. 
The GLUCOWATCH G2 Biographer is worn attached to 
FIELD OF THE INVENTION 
The invention is related to glucose monitors. 
BACKGROUND OF THE INVENTION 
10 the wrist, forearm or arm, like a wristwatch. The device 
measures blood glucose in real time with new readings dis-
played every 10 minutes and a trend arrow to indicate whether 
the blood glucose level is rising or falling. Both of these 
continuous monitors measure the glucose concentration 
15 within interstitial fluid glucose. 
The GLUCOWATCH® G2 Biographer contains two elec-
trodes, which pull salt from the skin, the salt carries water, and 
the water carries glucose. The glucose solution, which is a 
form of diluted interstitial fluid, is collected into a pad called 
Diabetes mellitus is a medical disorder characterized by 
persistent variable hyperglycemia (high blood sugar levels), 
resulting either from inadequate secretion of the hormone 
insulin, an inadequate response by the body's cells to insulin, 
or a combination of both of these factors. The most common 
forms of diabetes are type 1, type 2 and gestational diabetes. 
Diabetes is a disease that causes many complications in 
human normal function. As a result, the amount of glucose in 
the blood increases while the cells are starved of energy. Over 
the years, high blood glucose damages nerves and blood 
vessels, leading to complications such as blindness, heart and 
kidney disease, nerve problems, gum infections, and ampu-
tation. 
20 an Auto sensor. The Auto sensor component of the GLUCO-
WATCH® G2 Biographer must be replaced after 13 hours of 
readings are made. The glucose concentration is determined 
by an electrochemical reaction in the Autosensor. A calcula-
tion of the blood glucose level is made every ten minutes. A 
25 glucose reading is displayed on the watch face every twenty 
People with diabetes experiences symptoms such as feel-
ing tired, losing weight, feeling hungry or thirsty, urinating 30 
frequently or having vision problems. Symptoms can appear 
after 10 years or more living with the disease. 
This disease also represents the sixth-leading cause of 
death in USA. Prevention of diabetes-related complications 
can be accomplished through tight control of glucose levels in 35 
the blood. In the last decades many different glucose sensors 
have been developed. For example, existing glucose sensors 
and methods include near infrared spectroscopy, optical rota-
tion, enzymatic assays, fluorescence detection, a glucose 
sensing contact lenses, a biochemical catalyzed reaction 40 
embodied as a Continuous Glucose Monitor System 
(CGMS), and a product called GLUCOWATCH®. However, 
none of these sensors is fully non-invasive. 
The Continuous Glucose Monitoring System (Medtronic 
MiniMed, Northridge, Calif.) and the GLUCOWATCH® G2 45 
Biographer (Cygnus, Inc., Redwood City, Calif.) are 
reviewed below. These two devices, each approved by the 
FDA, measure a signal that is reportedly proportional to blood 
glucose. 
minutes. 
As described above, both the CGMS and GLUCOW-
ATCH® are invasive. Even a contact lens for monitoring 
glucose is somewhat invasive, besides being uncomfortable. 
What is needed is a portable, low cost, truly noninvasive 
glucose sensor that provides high sensitivity and no discom-
fort to the patient. 
SUMMARY 
A non-invasive method of sensing glucose in subjects 
includes the steps of providing a sensing solution including a 
metal ion from a metal salt, introducing a controlled amount 
of a bodily fluid sample from a subject into the sensing solu-
tion generating an optically-based parameter derived from 
directing incident light on the solution, and determining the 
presence of and/or the concentration of glucose in the bodily 
fluid using the parameter. The optical parameter can be 
observed by absorbance, reflection, scattering or transmis-
sion of light, which can be generated in the form of spectra. 
The light can be in the visible range or outside of the visible 
range of the electromagnetic spectrum. Tears can be used as 
the bodily fluid. The method can include a step of converting 
the concentration of glucose in the bodily fluid into a concen-
tration of glucose in the blood of the subject by the known 
relationship between the concentration of glucose in the fluid 
relative to the concentration of glucose in the blood. The 
metal salt can be a gold salt. The sensing solution can contain 
a promoter such as ammonium hydroxide. When the sensing 
solution includes metal nanoparticles, preferably the nano-
particles have an aspect ratio of 1.1to2.0 and more preferably 
have an aspect ratio of 1.2 to 1.8. These anisotropic metal 
nanoparticles can be gold nanorods or nanoplates. The sens-
ing solution can be heated to a temperature of 50° C. to 100° 
The first device for reading blood glucose levels continu- 50 
ously was approved by the U.S. Food and Drug Administra-
tion in June 1999. This device was the Continuous Glucose 
Monitor System (CGMS) manufactured by Medtronic Min-
iMed. The CGMS measures interstitial fluid glucose continu-
ously. It calculates and stores a reading every five minutes 55 
over a 72-hour period. The CGMS does not provide the glu-
cose results in real time, but rather downloads the readings 
after they have been collected, the way a 24-hour cardiac 
halter monitor provides information about cardiac rhythms 
after they have occurred. 60 C. 
The CGMS contains a wire with a supply of glucose oxi-
dase at the tip, which is inserted subcutaneously into the 
anterior abdominal wall. This same enzyme is used in many 
portable blood glucose monitors. Glucose oxidase catalyses a 
biochemical reaction in the presence of glucose and Oxygen 65 
that transfers electrons to a receiving molecule and creates an 
electronic current, whose magnitude can be measured and 
A non-invasive glucose monitoring system includes a 
means of drawing a sample of a body fluid without invasion of 
body tissue, a sample cell, a sensing solution of a metal salt 
for placing in the sample cell with the aliquot of the body 
fluid, a spectrophotometer including: a housing, a sample cell 
holder for receiving the sample cell, a light source, the light 
source providing light which irradiates a solution contained 
US 7,972,862 B2 
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in the sample cell, a photodetector for receiving light from the 
sample cell, and a microprocessor having stored software for 
determining glucose concentration in blood from spectro-
scopic data communicably connected to the detector, such 
that the microprocessor determines the glucose concentration 
from spectroscopic data provided by the detector, and a power 
supply, and instructions for use of the system. The power 
supply can be a battery. A preferred metal salt is a gold salt. 
The sensing solution can also include a promoter such as 
ammonium hydroxide. The sensing solution an also include 10 
metal nanoparticles that preferably have an aspect ratio of 1.1 
measurements in a wavelength range of 10 nm, or less, such 
as centered at around 560 nm for gold. 
In one embodiment of the invention ("nucleation 
method"), metal nanoparticles are nucleated in the solution 
upon reduction of metal ions when glucose is present in the 
sample. As the glucose concentration increases, it has been 
found that the number of nanoparticles increases, while the 
average size of the nanoparticles remains essentially the 
same. This allows the concentration of glucose in the body 
fluid to be determined using a spectroscopic method using the 
relationship given by the Beer-Lambert law. The concentra-
tion of nanoparticles is related to the measured absorbance 
via a single extinction coefficient for the uniform sized metal 
nanoparticles formed by the reduction of a dissolved metal 
salt to the metal particles. The relationship between the con-
centration of the nanoparticles and the glucose is inherent in 
the reaction stoichiometry when the average size of the par-
ticles is constant as in this nucleation method. 
to 2.0 and more preferably have an aspect ratio of 1.2 to 1.8. 
The metal nanoparticles can be nanospheres, nanorods or 
nanoplates. The spectrophotometer can include a heater and 15 
can include a visual or audible alarm if the measured level of 
glucose is a level that would be a danger for the subject 
providing the sample. The sensing solution can be provided in The extinction coefficient of the nanoparticle is ( E) related 
to the absorbance (A) as follows: a sealed sample cell which can be plastic. The system can also 
include a lachrymator so that the subject can produce tears on 20 
demand. 
BRIEF DESCRIPTION OF THE DRAWINGS 
A fuller understanding of the present invention and the 
features and benefits thereof will be obtained upon review of 
the following detailed description together with the accom-
panying drawings, in which: 
FIG. 1 shows an exemplary noninvasive glucose detector 
system according to an embodiment of the invention. 
FIG. 2 is a plot showing the absorbance of a sensing solu-
tion as a function of wavelength according to an embodiment 
of the invention in the wavelength range from 400 to 880 nm 
for a range of glucose concentrations from 0 to 20 mM. 
FIG. 3 is a plot showing the absorbance as a function of 
glucose concentration according to an embodiment of the 
invention at a wavelength near the gold nanoparticle absorp-
tion peak of about 560 nm. 
DETAILED DESCRIPTION 
A truly non-invasive method of sensing glucose comprises 
the steps of providing a sensing solution including a plurality 
of metal ions, and contacting a bodily fluid sample with the 
sensing solution. The bodily fluid sample is preferably tears. 
Metal nanoparticles are either formed (hereafter the "nucle-
ation method") or grown on metal seeds from metal ions in 
the sensing solution (hereafter the "seeding method") in the 
presence of glucose. A variety of metal ions can be used with 
the invention, including, but not limited to Au, Ag, Cu, Pd and 
where c is the concentration of nanoparticles and 1 is the path 
length of the sample. A linear relation has been found by the 
present Inventor between the absorbance and the glucose 
25 concentration for glucose concentrations as low as about 5 
mM using a gold salt at a wavelength of around 560 nm to give 
a constant average size gold nanoparticle as in the nucleation 
method (see Example 3 below). The concentration of the 
glucose in the spectrophotometry sample can be related to the 
30 body fluid sample by the volume of body fluid introduced to 
the sample. The relationship of glucose in the body fluid used 
can be converted to the concentration of glucose in the blood 
where the concentration profile for glucose in the body 
sample has been correlated to the profile of blood glucose 
35 levels. In another embodiment of the invention ("seeding 
method"), a plurality of anisotropic metal (e.g. gold) nano-
particles is provided in the sensing solution along with the 
plurality of metal ions. The sensing solution is then contacted 
with a bodily fluid sample. In the presence of glucose, the 
40 seeded particles grow in size with a change in the aspect ratio 
(AR) of the seed particles which results in a red shift in the 
peak of the longitudinal absorption band. Higher glucose 
concentrations have been found to result in larger red shifts. 
The shift can then be correlated with the glucose concentra-
45 ti on as in this case the change in the size of the metal nano-
particles is related through the glucose concentration by the 
reaction stoichiometry. Again the concentration in the body 
fluid can be calculated for a given volume of the body fluid 
added to the sample. 
Pt ions, where these metal ions can be readily reduced to the 50 
metallic state. Au has been found to undergo the desired 
reduction. The concentration of glucose in the body fluid is 
then determined which allows determination of the blood 
glucose concentration, if desired. 
Nanoparticle seeds can be obtained from a variety of 
sources, including commercial sources. As used herein, 
anisotropic seeds have particle shapes other than spherical 
displaying an aspect ratio (AR) of at least 1.1. It has been 
found that the higher the AR (e.g. length/diameter for a nano-
First, an optical method generates a parameter based on a 
change in at least one of absorption, reflectance and scattering 
of the metal nanoparticles resulting from the contacting step. 
In one embodiment of the reaction, absorption measurements 
are used. In the nucleation method, higher absorbance corre-
sponds to higher glucose levels. In the seeding method, the 
magnitude of the red shift in the peak of the longitudinal 
absorption band is related to the glucose concentration. In the 
second step the optical parameter is correlated with glucose 
concentration in the fluid. The glucose concentration in the 
fluid can then be converted into a glucose level in the blood of 
the subject. 
A full visible light spectrum can be used for analysis. 
However, useful information can be obtained by performing 
55 rod, or the area to thickness ratio for a nanoplate) of the 
nanoparticles, the better the dynamic range. However, for AR 
generally greater than about 2, sensitivity is reduced. Accord-
ingly, ARs are preferably in the range from 1.2 to 2.0, more 
preferably between 1.4and1.8 and most preferably about 1.6. 
In one embodiment of the seeding method, the metal nano-
60 particles include surfactant along at least a portion of their 
length. The surfactant present is generally associated with 
certain methods that can be used to form the nanoparticles. 
The metal nanoparticles formed in the presence of surfactant 
65 
are believed to display greater measurement sensitivity. 
In another embodiment essentially spherical seeds, nano-
spheres can be used and analysis upon measuring the absorp-
tion as described above for the "nucleating method". 
US 7,972,862 B2 
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Although nanospheres can be used with a diameter of 1 to 250 
nm or even greater, the extinction coefficient can not gener-
ally be treated as a constant for particles in excess of about 50 
nm, and corrections are generally included in the calculation 
of concentration of glucose. Nanosphere seeds having diam-
eters of 5 to 50 nm can be used, such as diameters of 5 to 10 
nm or diameters of about 5 nm. 
6 
ation method or grow in the seeding method during the oxi-
dation of glucose. Gluconic acid is the carboxylic acid forms 
by the oxidation of the first carbon of glucose and has the 
chemical formula C6H120 7 . In the nucleation method as more 
nanospheres form, absorption at the wave length of 560 nm 
changes proportionally to the glucose concentration. In the 
seeding method, as the AR of the nanoparticles change, a 
resulting red shift of the wavelength of the peak absorption 
can be directly correlated to the amount of glucose oxidized. 
In the nucleation method a surfactant may also be added to 
the sensing solution. Certain surfactants referred to as coor-
dinating surfactants can be used to control the shape of the 
nanoparticles formed, such as to form shapes other than gen-
erally spherical particles which have been found to form in 
the absence of a surfactant. 
10 In either method, the absorbance spectruni (or portion 
thereof) can be measured using a UV-Vis spectrometer, which 
can be as small as a cigarette box, or even smaller. 
Thus, as shown above, the open chain aldehyde form of 
glucose acts as a reducing agent and reacts with a metal salt to 
15 form metal nanoparticles in the nucleation method or modify 
theAR in the seeding method. An above ambient temperature, 
such as about 50 to about 100° C. can be used to increase the 
reaction rate. 
Body fluids in which glucose is found is known to include 
blood, saliva, urine and tears. Thus, a variety of body fluids 
can be used with the invention. However, the glucose concen-
tration in tears correlates well with the blood glucose concen-
tration. Accordingly, in an embodiment of the invention the 
body fluid is tears. Moreover, tears include a minimum of 20 
potentially interfering materials found in other body fluids 
such as saliva. It is believed that a couple of tears will be more 
than enough to provide a sufficient body fluid volume to 
determine the glucose concentration. The volume of tears 
necessary will depend on the glucose concentration in the 25 
tears, so diabetics potentially need smaller tear samples than 
non-diabetics need. It may be necessary in some applications 
to induce a subject to cry, such as by using onions or other 
lachrymators to induce tearing. 
Results obtained using silver salts for the nucleation 
method have provided useful results. However, gold salts 
were found to provide much better results. An exemplary 
reaction for an exemplary gold salt is shown below. The 
reaction product is gold nanoparticles (nanospheres (NS) 
absent surfactant addition) shown in reaction (3) below: 
(3) 
Glucose AuNS solution 
Although not needed to practice the present invention and 30 
not seeking to be bound to the theory presented, reaction 
details follow that are believed to be operable. The operable 
generalized reaction utilized by the invention is a redox reac-
tion where glucose functions as the reducing agent according 
2%NJLiOH 
l'J. 
Heating above room temperature can accelerate of the nano-
particle formation and growth, as noted above, where the 
solution can be heated, for example to a temperature of70 to 
to the following (only reduction product shown): 
1. (nucleation method) metal salt+glucose--;.metal nano-
particles form. 
2. (seeding method) metal salt+glucose+anisotropic metal 
nanoparticle seeds--;.metal nanoparticles grow and theAR of 
the nanoparticles change due to the growth. 
The above reactions are believed to be made possible based 
on the equilibrium of glucose in solution between the open-
chain aldehyde alcohol form and the cyclic hemiacetal form 
35 80° C. Ammonium hydroxide shown above has been found to 
promote the reaction. 
The invention has been found to provide a low limit of 
detection as is described in the example below for the use of 
a gold salt. The invention gives highly selective, reliable, and 
40 reproducible results and can be embodied in a system that is 
portable, simple, low cost and noninvasive (no painful test-
ing). 
as shown in schematic (1) below. The presence of the alde-
hyde can be detected through a reaction with chloroauric acid 45 
in aqueous solution, in a manner similar to the Toll en's silver 
mirror test for aldehydes shown as (2) below. 
A schematic of an exemplary glucose detector system 100 
according to an embodiment of the invention is shown in FIG. 
1. System 100 includes a housing 105 having a sample cell 
holder 110 of appropriate dimensions for insertion of a 
sample cell 115 such that the proper orientation for the trans-
mission of light from a light source 120 to a photodetector 
125, where a light path is shown by a dashed line in FIG. 1, is 
achieved and the system can be sealed from light external to 
the housing 105. The sealing of the light can be by any means H H 
(l) 50 
0 HO 
H OH H OH 
HO H 
-
HO H 
H OH H OH 
H OH H 0 
CH20H CH20H 
(2) 
RC(O)H + 2 Ag(NH3)iOH 
-
In the presence of a gluconic acid salt, which is believed to 
stabilize metal nanoparticles, nanospheres form in the nucle-
such as a door, cap, or plug associated with the housing 105, 
sample cell holder 110 and/or sample cell 115. The sample 
cell 115 can also be used to store a desired concentration of a 
55 metal salt solution for mixture with the prescribed quantity of 
the body fluid. Although shown as a direct light path in FIG. 
1, the system can include mirrors, lenses, and diffraction 
gratings (not shown) as required to deliver the light as desired 
60 
to the photodetector 125. 
In general, the sample cell 115 can be made from any 
material of sufficient transparency at the range of wave-
lengths used for the analysis of the sample. The sample cell 
115 can be sufficiently small such that the volume of a single 
tear can be mixed with a smaller volume of a sensing solution 
65 containing a metal salt. The volume of the sample cell can be 
about 0.1 to about 1 mL or greater. The material forthe sample 
cell 115 can be quartz, glass, or a plastic. Battery 130, such as 
US 7,972,862 B2 
7 
a lithium ion battery, provides power for the various compo-
nents of system 100. Microprocessor 135 includes associated 
memory which stores operating software. Microprocessor 
135 is communicably connected to light source 120. Light 
source 120 provides light which irradiates a solution con-
tained in sample cell 115. Photodetector 125 receives light 
transmitted through the solution in sample cell 115 and con-
verts the light into an electrical signal. The electrical signal is 
communicated to microprocessor 135. Microprocessor 135 
determines the glucose concentration from data provided by 
10 detector 125. The microprocessor 135 can instruct the collec-
tion of multiple readings of the optical signal over time such 
that the complete oxidation of the glucose in the sample can 
be assured by determining that a maximum signal is reached. 
Additionally, a means of controlled heating (not shown) of 
sample cell 115 to a predetermined temperature can be 15 
included. In a preferred embodiment, ifthe glucose concen-
tration is above or below a predetermined concentration, 
microprocessor commands a light (e.g. blinking red light) or 
audible alarm 140 to activate. The alarm can also be used to 
convey other information, such as the viability of the sample 20 
for subsequent reuse. Although not shown, system 100 can 
include a transmitter and antenna to allow data to be moni-
tored at a remote location. 
8 
presence of various concentrations of glucose in an ammo-
nium hydroxide 2% solution. The concentration of glucose in 
solution varied from 0 to 20 mM. The reaction was performed 
at about 70° C. FIG. 2 shows the absorbance of the sensing 
solution as a function of wavelength in the wavelength range 
from 400 to 880 nm where glucose was added to achieve 
solution concentrations from 0 to 20 mM. An absorption peak 
can be seen at about 560 nm where higher glucose concen-
trations resulted in higher measured absorbance levels. 
FIG. 3 shows the absorbance dated shown in FIG. 2 at a 
wavelength near the gold nanoparticle absorption peak of 
about 560 nm. As shown in FIG. 3, the higher the glucose 
concentration, from about 6 mM to 20 mM, the higher the 
value of the absorbance. The relationship is linear. A level of 
6.1 mM glucose in the tear is known to correspond to about a 
110 mg/dL glucose level in the blood, which is in the normal 
blood glucose range from 70 to 110 mg/dL. Due to the rela-
tionship between the glucose level in tears and the glucose 
level in blood, the relationship between measured absorbance 
and blood glucose can be stored, such as in a non-volatile 
memory in a microprocessor-based system including a spec-
trophotometer. The measured absorbance provided by a spec-
trophotometer allows the determination of the blood glucose 
level by the relationship of the nanoparticle concentration to 
25 the glucose concentration from the body sample aliquot and 
the relationship of the glucose level of a body sample to the 
blood level. The dependence of the absorbance of the gold 
nanoparticles solution with glucose concentrations as low as 
that in common in non-diabetic tears, several mM, makes 
In operation, a user will provide a tear sample and place a 
predetermined volume of the tear sample into sample cell 
115. The specific volume of a sensing solution including a 
specific concentration of a metal salt can then be added and 
the components mixed as needed. Alternately, the opposite 
order of addition of reagents can be carried out. In one 
embodiment the sample cell 115 is provided with a sealed 
sensing solution of a specific concentration and volume 
which has been programmed into the microprocessor such 
that the sample can be formed upon introduction of a specific 
volume of the body fluid either through the seal or upon 
removal of the seal. In another embodiment the sample cell 
can be used for the collection of a sample of the bodily fluid 35 
and a specific portion of the sensing solution of a metal salt 
can be introduced to the sample cell 115. Sample cell 115 is 
then inserted into system 100 and the measurement process is 
begun. The microprocessor can then determine the glucose 
present in the bodily fluid by performing a differential mea- 40 
surement. Following use, contents of the sample cell 115 can 
30 sensors according to the invention suitable for direct applica-
tions in biomedical sensing, including measurements by the 
subjects themselves. 
be disposed of, or stored and subsequently reused depending 
upon the amount of metal salt remaining in the sample cell 
which can be calculated from the measured optical signal. If 
reused, an initial optical measurement can be made prior to 45 
adding the bodily fluid or the stored previous measurement 
can be used in the determination of the glucose level. The 
magnitude of the optical measurement can be used to deter-
mine the viability of reusing the sample cell. 
Using the glucose measurement, diagnosing diabetes and a 50 
variety of other diseases which are associated with an 
increase or decrease in glucose can be realized. Regarding 
diabetes, the detection limit is low enough to detect levels of 
glucose in healthy persons. Using the inventive method, 
potential diabetic problems can be detected before diabetes 55 
has been diagnosed. 
EXAMPLES 
It should be understood that the Examples described below 60 
are provided for illustrative purposes only and do not in any 
way define the scope of the invention. 
Nucleation Embodiment 
Gold nanospheres were synthesized using a 2.4x10-5 M 
chloroauric acid tri-hydrated (HAuC14 .3H20) solution, in the 
65 
It is to be understood that while the invention has been 
described in conjunction with the preferred specific embodi-
ments thereof, that the foregoing description as well as the 
examples which follow are intended to illustrate and not limit 
the scope of the invention. Other aspects, advantages and 
modifications within the scope of the invention will be appar-
ent to those skilled in the art to which the invention pertains. 
The Abstract of the Disclosure is provided to comply with 
37 C.F.R. §1.72(b), requiring an abstract that will allow the 
reader to quickly ascertain the nature of the technical disclo-
sure. It is submitted with the understanding that it will not be 
used to interpret or limit the scope or meaning of the follow-
ing claims. 
I claim: 
1. A method of determining glucose concentrations m 
bodily fluids, comprising: 
providing a sensing solution comprising a plurality of 
metal ions; 
introducing a bodily fluid sample from a subject into said 
sensing solution, wherein if glucose is present in said 
bodily fluid sample said glucose reduces said plurality of 
metal ions to form metal nanoparticles or increases a 
size of metal nanoparticle seeds if said metal nanopar-
ticle seeds are also provided in said sensing solution; 
directing incident light at said sensing solution after said 
introducing; 
measuring at least one optically-based parameter respon-
sive to said directing of said incident light, and 
determining a concentration of said glucose in said bodily 
fluid sample based on an amplitude of said optically-
based parameter wherein a higher absorbance corre-
sponds to a higher glucose concentration or a magnitude 
of a red wavelength shift of a peak absorption wave-
length when said metal nanoparticle seeds are provided 
in said sensing solution and said optically-based param-
US 7,972,862 B2 
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eter is wavelength, wherein a higher red wavelength 
shift corresponds to a higher glucose concentration. 
2. The method of claim 1, wherein said optically-based 
parameter comprises absorbance, reflection, scattering or 
transmission of said incident light. 
3. The method of claim 1, wherein said measuring com-
prises generating a spectrum. 
10 
or increases a size of metal nanoparticle seeds if metal 
nanoparticle seeds are also provided in said sensing 
solution; and 
a spectrophotometer including a light source for measuring 
at least one optically-based parameter responsive to light 
from said light source directed at said sample cell, and a 
microprocessor that includes associated memory for 
determining a concentration of said glucose in said 
bodily fluid sample based on an amplitude of said opti-4. The method of claim 1, wherein said bodily fluid sample 
comprises tear fluid. 
5. The method of claim 1, further optionally comprising 10 
converting said concentration of glucose into a concentration 
cally-based parameter or a wavelength shift of a peak 
absorption wavelength when said nanoparticle seeds are 
provided in said sensing solution and said optically-
of glucose in blood of said subject using a correlation relation 
between a glucose concentration in said bodily fluid sample 
and glucose concentration in said blood. 
6. The method of claim 1, wherein said plurality of metal 
ions comprise gold ions. 
7. The method of claim 1, wherein said sensing solution 
further comprises a promoter that promotes said glucose 
reducing said plurality of metal ions. 
8. The method of claim 7, wherein said promoter comprises 
ammonium hydroxide. 
9. The method of claim 1, wherein said sensing solution 
further comprises said metal nanoparticle seeds, said metal 
nanoparticle seeds comprising a plurality of anisotropic metal 
nanoparticles, and said optically-based parameter comprises 
said wavelength shift. 
10. The method of claim 9, wherein said plurality of aniso-
tropic metal nanoparticles have an aspect ratio of 1.2 to 1.8. 
11. The method of claim 9, wherein said plurality of aniso-
tropic metal nanoparticles comprise gold nanorods or nano-
plates. 
12. The method of claim 1, further comprising heating said 
sensing solution to a temperature of 50° C. to 100° C. 
13. A glucose monitoring system, comprising: 
a sample cell; 
a sensing solution comprising a solution comprising a plu-
rality of metal ions in said sample cell together with a 
bodily fluid sample from a subject, wherein if glucose is 
present in said bodily fluid sample said glucose reduces 
said plurality of metal ions to form metal nanoparticles 
15 
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based parameter is wavelength. 
14. The system of claim 13, wherein said plurality of metal 
ions comprises gold ions. 
15. The system of claim 13, wherein said sensing solution 
further comprising a promoter that promotes said glucose 
reducing said plurality of metal ions. 
16. The system of claim 15, wherein said promoter com-
prises animonia hydroxide. 
17. The system of claim 13, wherein said sensing solution 
further comprises said metal nanoparticle seeds, said metal 
nanoparticle seeds comprising a plurality of anisotropic metal 
nanoparticles. 
18. The system of claim 17, wherein said plurality of aniso-
25 tropic metal nanoparticles have an aspect ratio of 1.1 to 2.0. 
19. The system of claim 17, wherein said plurality of aniso-
tropic metal nanoparticles have an aspect ratio of 1.2 to 1.8. 
20. The system method of claim 18, wherein said plurality 
of anisotropic metal nanoparticles comprise nanospheres, 
30 nanorods or nanoplates. 
35 
21. The system of claim 13, wherein said spectrophotom-
eter further comprising a visual or audible alarm. 
22. The system of claim 13, wherein said sensing solution 
is provided in a sealed sample cell. 
23. The system of claim 13, wherein a correlation relation 
between glucose concentration in said bodily fluid sample 
and a glucose concentration in blood is stored in said memory, 
and wherein said microprocessor converts said concentration 
of glucose in said bodily fluid sample into a concentration of 
40 glucose in blood of said subject. 
* * * * * 
